STOCKHOLM, SWEDEN--(Marketwire - June 18, 2012) - Swedish Orphan Biovitrum AB (Sobi) issues a 5-year SEK 600 million senior unsecured bond. The bond has a floating interest of 3 months Stibor + 500 bps with maturity in 2017.
The transaction closes ahead of the expected closing date as a result of strong investor demand. The bond will be issued on 26 June 2012. Sobi will apply for the loan to be listed on NASDAQ OMX Stockholm.
The bond will replace Sobi’s existing term facility and will improve the financial flexibility as well as extend the maturity profile of Sobi’s debt. The transaction was led by Nordea and SEB.
Swedish Orphan Biovitrum (Sobi) Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 18 June 2012 at 13.00 CET.
Sobi Press Release June 18, 2012 in pdf format: http://hugin.info/134557/R/1620262/517608.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE [HUG#1620262]
For further information, please contact:
Lars Sandstrom
CFO
Tel.: +46 8 697 26 33
